Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88


Anti-HER2 scFv-directed extracellular vesicle-mediated mRNA-based gene delivery inhibits growth of HER2-positive human breast tumor xenografts by prodrug activation.

Wang JH, Forterre AV, Zhao J, Frimannsson DO, Delcayre A, Antes TJ, Efron B, Jeffrey SS, Pegram MD, Matin AC.

Mol Cancer Ther. 2018 Feb 26. pii: molcanther.0827.2017. doi: 10.1158/1535-7163.MCT-17-0827. [Epub ahead of print]


Fast and Label-Free Isolation of Circulating Tumor Cells from Blood: From a Research Microfluidic Platform to an Automated Fluidic Instrument, VTX-1 Liquid Biopsy System.

Lemaire CA, Liu SZ, Wilkerson CL, Ramani VC, Barzanian NA, Huang KW, Che J, Chiu MW, Vuppalapaty M, Dimmick AM, Carlo DD, Kochersperger ML, Crouse SC, Jeffrey SS, Englert RF, Hengstler S, Renier C, Sollier-Christen E.

SLAS Technol. 2018 Feb;23(1):16-29. doi: 10.1177/2472630317738698.


Workflow optimization of whole genome amplification and targeted panel sequencing for CTC mutation detection.

Liu HE, Triboulet M, Zia A, Vuppalapaty M, Kidess-Sigal E, Coller J, Natu VS, Shokoohi V, Che J, Renier C, Chan NH, Hanft VR, Jeffrey SS, Sollier-Christen E.

NPJ Genom Med. 2017 Nov 1;2:34. doi: 10.1038/s41525-017-0034-3. eCollection 2017.


T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire.

Beausang JF, Wheeler AJ, Chan NH, Hanft VR, Dirbas FM, Jeffrey SS, Quake SR.

Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):E10409-E10417. doi: 10.1073/pnas.1713863114. Epub 2017 Nov 14.


5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages.

Song CX, Yin S, Ma L, Wheeler A, Chen Y, Zhang Y, Liu B, Xiong J, Zhang W, Hu J, Zhou Z, Dong B, Tian Z, Jeffrey SS, Chua MS, So S, Li W, Wei Y, Diao J, Xie D, Quake SR.

Cell Res. 2017 Oct;27(10):1231-1242. doi: 10.1038/cr.2017.106. Epub 2017 Aug 18.


Profiling protein expression in circulating tumour cells using microfluidic western blotting.

Sinkala E, Sollier-Christen E, Renier C, Rosàs-Canyelles E, Che J, Heirich K, Duncombe TA, Vlassakis J, Yamauchi KA, Huang H, Jeffrey SS, Herr AE.

Nat Commun. 2017 Mar 23;8:14622. doi: 10.1038/ncomms14622.


Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.

Kidess-Sigal E, Liu HE, Triboulet MM, Che J, Ramani VC, Visser BC, Poultsides GA, Longacre TA, Marziali A, Vysotskaia V, Wiggin M, Heirich K, Hanft V, Keilholz U, Tinhofer I, Norton JA, Lee M, Sollier-Christen E, Jeffrey SS.

Oncotarget. 2016 Dec 20;7(51):85349-85364. doi: 10.18632/oncotarget.13350.


Label-free enumeration, collection and downstream cytological and cytogenetic analysis of circulating tumor cells.

Dhar M, Pao E, Renier C, Go DE, Che J, Montoya R, Conrad R, Matsumoto M, Heirich K, Triboulet M, Rao J, Jeffrey SS, Garon EB, Goldman J, Rao NP, Kulkarni R, Sollier-Christen E, Di Carlo D.

Sci Rep. 2016 Oct 14;6:35474. doi: 10.1038/srep35474.


Electropermanent magnet actuation for droplet ferromicrofluidics.

Padovani JI, Jeffrey SS, Howe RT.

Technology (Singap World Sci). 2016 Jun;4(2):110-119. Epub 2016 May 13.


Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy.

Renier C, Do J, Reyna-Neyra A, Foster D, De A, Vogel H, Jeffrey SS, Tse V, Carrasco N, Wapnir I.

Oncotarget. 2016 Aug 23;7(34):54811-54824. doi: 10.18632/oncotarget.10238.


Circulating tumor cell technologies.

Ferreira MM, Ramani VC, Jeffrey SS.

Mol Oncol. 2016 Mar;10(3):374-94. doi: 10.1016/j.molonc.2016.01.007. Epub 2016 Jan 28. Review.


Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology.

Che J, Yu V, Dhar M, Renier C, Matsumoto M, Heirich K, Garon EB, Goldman J, Rao J, Sledge GW, Pegram MD, Sheth S, Jeffrey SS, Kulkarni RP, Sollier E, Di Carlo D.

Oncotarget. 2016 Mar 15;7(11):12748-60. doi: 10.18632/oncotarget.7220.


High efficiency vortex trapping of circulating tumor cells.

Dhar M, Wong J, Karimi A, Che J, Renier C, Matsumoto M, Triboulet M, Garon EB, Goldman JW, Rettig MB, Jeffrey SS, Kulkarni RP, Sollier E, Di Carlo D.

Biomicrofluidics. 2015 Dec 17;9(6):064116. doi: 10.1063/1.4937895. eCollection 2015 Nov.


Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.

Ignatiadis M, Lee M, Jeffrey SS.

Clin Cancer Res. 2015 Nov 1;21(21):4786-800. doi: 10.1158/1078-0432.CCR-14-1190. Review.


HIGD1A Regulates Oxygen Consumption, ROS Production, and AMPK Activity during Glucose Deprivation to Modulate Cell Survival and Tumor Growth.

Ameri K, Jahangiri A, Rajah AM, Tormos KV, Nagarajan R, Pekmezci M, Nguyen V, Wheeler ML, Murphy MP, Sanders TA, Jeffrey SS, Yeghiazarians Y, Rinaudo PF, Costello JF, Aghi MK, Maltepe E.

Cell Rep. 2015 Feb 12. pii: S2211-1247(15)00033-9. doi: 10.1016/j.celrep.2015.01.020. [Epub ahead of print]


Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform.

Kidess E, Heirich K, Wiggin M, Vysotskaia V, Visser BC, Marziali A, Wiedenmann B, Norton JA, Lee M, Jeffrey SS, Poultsides GA.

Oncotarget. 2015 Feb 10;6(4):2549-61.


High-throughput time-resolved FRET reveals Akt/PKB activation as a poor prognostic marker in breast cancer.

Veeriah S, Leboucher P, de Naurois J, Jethwa N, Nye E, Bunting T, Stone R, Stamp G, Calleja V, Jeffrey SS, Parker PJ, Larijani B.

Cancer Res. 2014 Sep 15;74(18):4983-95. doi: 10.1158/0008-5472.CAN-13-3382. Epub 2014 Jun 26.


Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.

Deng G, Krishnakumar S, Powell AA, Zhang H, Mindrinos MN, Telli ML, Davis RW, Jeffrey SS.

BMC Cancer. 2014 Jun 19;14:456. doi: 10.1186/1471-2407-14-456.


Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.

Zhang H, Cohen AL, Krishnakumar S, Wapnir IL, Veeriah S, Deng G, Coram MA, Piskun CM, Longacre TA, Herrler M, Frimannsson DO, Telli ML, Dirbas FM, Matin AC, Dairkee SH, Larijani B, Glinsky GV, Bild AH, Jeffrey SS.

Breast Cancer Res. 2014 Apr 7;16(2):R36. doi: 10.1186/bcr3640.


Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips.

Earhart CM, Hughes CE, Gaster RS, Ooi CC, Wilson RJ, Zhou LY, Humke EW, Xu L, Wong DJ, Willingham SB, Schwartz EJ, Weissman IL, Jeffrey SS, Neal JW, Rohatgi R, Wakelee HA, Wang SX.

Lab Chip. 2014 Jan 7;14(1):78-88. doi: 10.1039/c3lc50580d.


Impact of navigation on knowledge and attitudes about clinical trials among Chinese patients undergoing treatment for breast and gynecologic cancers.

Clair McClung E, Davis SW, Jeffrey SS, Kuo MC, Lee MM, Teng NN.

J Immigr Minor Health. 2015 Jun;17(3):976-9. doi: 10.1007/s10903-013-9901-x.


Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?

Kidess E, Jeffrey SS.

Genome Med. 2013 Aug 13;5(8):70. doi: 10.1186/gm474. eCollection 2013. No abstract available.


Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis.

Kin C, Kidess E, Poultsides GA, Visser BC, Jeffrey SS.

Expert Rev Mol Diagn. 2013 Jul;13(6):581-99. doi: 10.1586/14737159.2013.811896. Review.


Nuclear localization of the mitochondrial factor HIGD1A during metabolic stress.

Ameri K, Rajah AM, Nguyen V, Sanders TA, Jahangiri A, Delay M, Donne M, Choi HJ, Tormos KV, Yeghiazarians Y, Jeffrey SS, Rinaudo PF, Rowitch DH, Aghi M, Maltepe E.

PLoS One. 2013 Apr 30;8(4):e62758. doi: 10.1371/journal.pone.0062758. Print 2013.


Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines.

Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, Sheth S, Kurian AW, Ford JM, Stockdale FE, Quake SR, Pease RF, Mindrinos MN, Bhanot G, Dairkee SH, Davis RW, Jeffrey SS.

PLoS One. 2012;7(5):e33788. doi: 10.1371/journal.pone.0033788. Epub 2012 May 7.


Multiplex molecular analysis of CTCs.

Sieuwerts AM, Jeffrey SS.

Recent Results Cancer Res. 2012;195:125-40. doi: 10.1007/978-3-642-28160-0_11. Review.


A pharmacogenomic method for individualized prediction of drug sensitivity.

Cohen AL, Soldi R, Zhang H, Gustafson AM, Wilcox R, Welm BE, Chang JT, Johnson E, Spira A, Jeffrey SS, Bild AH.

Mol Syst Biol. 2011 Jul 19;7:513. doi: 10.1038/msb.2011.47.


Distinctive responsiveness to stromal signaling accompanies histologic grade programming of cancer cells.

Luciani MG, Seok J, Sayeed A, Champion S, Goodson WH, Jeffrey SS, Xiao W, Mindrinos M, Davis RW, Dairkee SH.

PLoS One. 2011;6(5):e20016. doi: 10.1371/journal.pone.0020016. Epub 2011 May 19.


Adipose levels of polybrominated diphenyl ethers and risk of breast cancer.

Hurley S, Reynolds P, Goldberg D, Nelson DO, Jeffrey SS, Petreas M.

Breast Cancer Res Treat. 2011 Sep;129(2):505-11. doi: 10.1007/s10549-011-1481-7. Epub 2011 Apr 6.


Stem cells in human breast cancer.

Oliveira LR, Jeffrey SS, Ribeiro-Silva A.

Histol Histopathol. 2010 Mar;25(3):371-85. doi: 10.14670/HH-25.371. Review.


Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype.

Ameri K, Luong R, Zhang H, Powell AA, Montgomery KD, Espinosa I, Bouley DM, Harris AL, Jeffrey SS.

Br J Cancer. 2010 Feb 2;102(3):561-9. doi: 10.1038/sj.bjc.6605491. Epub 2010 Jan 5.


Focal amplification and oncogene dependency of GAB2 in breast cancer.

Bocanegra M, Bergamaschi A, Kim YH, Miller MA, Rajput AB, Kao J, Langerød A, Han W, Noh DY, Jeffrey SS, Huntsman DG, Børresen-Dale AL, Pollack JR.

Oncogene. 2010 Feb 4;29(5):774-9. doi: 10.1038/onc.2009.364. Epub 2009 Nov 2.


CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer.

Bergamaschi A, Kim YH, Kwei KA, La Choi Y, Bocanegra M, Langerød A, Han W, Noh DY, Huntsman DG, Jeffrey SS, Børresen-Dale AL, Pollack JR.

Mol Oncol. 2008 Dec;2(4):327-39. doi: 10.1016/j.molonc.2008.09.004. Epub 2008 Oct 2.


Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device.

Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W, Xiao W, Davis MM, Pease RF, Mindrinos MN, Jeffrey SS, Davis RW.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3970-5. doi: 10.1073/pnas.0813188106. Epub 2009 Feb 20.


Cancer biomarker profiling with microRNAs.

Jeffrey SS.

Nat Biotechnol. 2008 Apr;26(4):400-1. doi: 10.1038/nbt0408-400. No abstract available.


Basal carcinoma of the breast revisited: an old entity with new interpretations.

Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H.

J Clin Pathol. 2008 May;61(5):553-60. doi: 10.1136/jcp.2008.055475. Epub 2008 Mar 6. Review.


New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients.

Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, Rouse RV, Bailey L, Philben VJ, Dirbas FM, Dunn JJ, Johnson DL, Wapnir IL, Carlson RW, Stockdale FE, Hansen NM, Jeffrey SS; Bay Area SLN Study.

BMC Cancer. 2008 Mar 4;8:66. doi: 10.1186/1471-2407-8-66.


DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.

Han W, Jung EM, Cho J, Lee JW, Hwang KT, Yang SJ, Kang JJ, Bae JY, Jeon YK, Park IA, Nicolau M, Jeffrey SS, Noh DY.

Genes Chromosomes Cancer. 2008 Jun;47(6):490-9. doi: 10.1002/gcc.20550.


Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression.

Wang Y, Ikeda DM, Narasimhan B, Longacre TA, Bleicher RJ, Pal S, Jackman RJ, Jeffrey SS.

Radiology. 2008 Feb;246(2):367-75. doi: 10.1148/radiol.2462070169. Epub 2008 Jan 7.


Cell trapping in activated micropores for functional analysis.

Talasaz AH, Powell AA, Stahl P, Ronaghi M, Jeffrey SS, Mindrinos M, Davis RW.

Conf Proc IEEE Eng Med Biol Soc. 2006;1:1838-41. Review.


Transcriptomic signatures in breast cancer.

Fu J, Jeffrey SS.

Mol Biosyst. 2007 Jul;3(7):466-72. Epub 2007 Jun 5. Review.


TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.

Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS.

Breast Cancer Res. 2007;9(3):R30.


Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome.

Dairkee SH, Nicolau M, Sayeed A, Champion S, Ji Y, Moore DH, Yong B, Meng Z, Jeffrey SS.

Oncogene. 2007 Sep 20;26(43):6269-79. Epub 2007 Apr 30.


Disease-specific genomic analysis: identifying the signature of pathologic biology.

Nicolau M, Tibshirani R, Børresen-Dale AL, Jeffrey SS.

Bioinformatics. 2007 Apr 15;23(8):957-65. Epub 2007 Feb 3.


Discovery and validation of breast cancer subtypes.

Kapp AV, Jeffrey SS, Langerød A, Børresen-Dale AL, Han W, Noh DY, Bukholm IR, Nicolau M, Brown PO, Tibshirani R.

BMC Genomics. 2006 Sep 11;7:231. Erratum in: BMC Genomics. 2007 Apr 13;8(1):101.


Radiation-induced effects on gene expression: an in vivo study on breast cancer.

Helland A, Johnsen H, Frøyland C, Landmark HB, Saetersdal AB, Holmen MM, Gjertsen T, Nesland JM, Ottestad W, Jeffrey SS, Ottestad LO, Rodningen OK, Sherlock G, Børresen-Dale AL.

Radiother Oncol. 2006 Aug;80(2):230-5. Epub 2006 Aug 4.


MRI-guided needle localization of suspicious breast lesions: results of a freehand technique.

van den Bosch MA, Daniel BL, Pal S, Nowels KW, Birdwell RL, Jeffrey SS, Ikeda DM.

Eur Radiol. 2006 Aug;16(8):1811-7. Epub 2006 May 9.


Lysyl oxidase is essential for hypoxia-induced metastasis.

Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ.

Nature. 2006 Apr 27;440(7088):1222-6.


Supplemental Content

Loading ...
Support Center